NASDAQ:AERI

Aerie Pharmaceuticals Stock Forecast, Price & News

$15.07

+1.12 (+8.03 %)

(As of 01/19/2021 12:00 AM ET)

Add

Compare

Today's Range

$14.02

Now: $15.07▼

$15.28

50-Day Range

$12.05

MA: $13.40▼

$14.49

52-Week Range

$9.01

Now: $15.07▼

$23.04

Volume1.60 million shs

Average Volume547,740 shs

Market Capitalization$705.50 million

P/E RatioN/A

Dividend YieldN/A

Beta0.79

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

MarketRank^™

Overall MarketRank^™

1.71 out of 5 stars

3.3 Analyst's Opinion

Consensus Rating
Aerie Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 9 buy ratings, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $26.36, Aerie Pharmaceuticals has a forecasted upside of 74.9% from its current price of $15.07.
Amount of Analyst Coverage
Aerie Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
Aerie Pharmaceuticals has received 777 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Aerie Pharmaceuticals has received 541 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Aerie Pharmaceuticals has received 58.95% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote “Outperform” if you believe AERI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AERI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Aerie Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Aerie Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aerie Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $94,965.00 in company stock.
Percentage Held by Insiders
Only 9.72% of the stock of Aerie Pharmaceuticals is held by insiders.
Percentage Held by Institutions
99.89% of the stock of Aerie Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Aerie Pharmaceuticals are expected to grow in the coming year, from ($3.76) to ($2.49) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aerie Pharmaceuticals is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aerie Pharmaceuticals is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aerie Pharmaceuticals has a P/B Ratio of 4.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:AERI

Previous Symbol

CUSIPN/A

CIK1337553

Webwww.aeriepharma.com

Phone919-237-5300

Employees380

Debt

Debt-to-Equity Ratio3.41

Current Ratio3.33

Quick Ratio3.10

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$69.89 million

Price / Sales10.09

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.60 per share

Price / Book4.19

Profitability

EPS (Most Recent Fiscal Year)($3.40)

Net Income$-199,580,000.00

Net Margins-231.05%

Return on Equity-135.57%

Return on Assets-37.23%

Miscellaneous

Outstanding Shares46,815,000

Market Cap$705.50 million

Next Earnings Date2/18/2021 (Estimated)

OptionableOptionable

$15.07

+1.12 (+8.03 %)

(As of 01/19/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive AERI News and Ratings via Email

Sign-up to receive the latest news and ratings for AERI and its competitors with MarketBeat's FREE daily newsletter.

Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions

How has Aerie Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Aerie Pharmaceuticals' stock was trading at $14.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AERI stock has increased by 3.6% and is now trading at $15.07.
View which stocks have been most impacted by COVID-19.

Is Aerie Pharmaceuticals a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aerie Pharmaceuticals stock.
View analyst ratings for Aerie Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Aerie Pharmaceuticals?

Wall Street analysts have given Aerie Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aerie Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aerie Pharmaceuticals' next earnings date?

Aerie Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for Aerie Pharmaceuticals.

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced its quarterly earnings results on Tuesday, November, 10th. The company reported ($0.65) EPS for the quarter, topping analysts' consensus estimates of ($0.81) by $0.16. The business earned $20.08 million during the quarter, compared to the consensus estimate of $19.23 million. Aerie Pharmaceuticals had a negative net margin of 231.05% and a negative return on equity of 135.57%.
View Aerie Pharmaceuticals' earnings history.

What price target have analysts set for AERI?

12 brokers have issued twelve-month target prices for Aerie Pharmaceuticals' shares. Their forecasts range from $9.00 to $40.00. On average, they anticipate Aerie Pharmaceuticals' share price to reach $26.36 in the next twelve months. This suggests a possible upside of 74.9% from the stock's current price.
View analysts' price targets for Aerie Pharmaceuticals or view Wall Street analyst' top-rated stocks.

Who are some of Aerie Pharmaceuticals' key competitors?

Some companies that are related to Aerie Pharmaceuticals include AlloVir (ALVR), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Bavarian Nordic A/S (BVNRY), NantKwest (NK), Replimune Group (REPL), Scholar Rock (SRRK), REGENXBIO (RGNX), Vericel (VCEL), Translate Bio (TBIO), C4 Therapeutics (CCCC), BioCryst Pharmaceuticals (BCRX), Forma Therapeutics (FMTX), Atara Biotherapeutics (ATRA) and Inhibrx (INBX).
View all of AERI's competitors.

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include (CGC), Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the following people:

Dr. Vicente J. Anido Jr., CEO & Chairman (Age 67, Pay $1.13M)
Mr. Thomas A. Mitro, Pres & COO (Age 62, Pay $582.78k)
Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 59, Pay $582.51k)
Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 62, Pay $620.37k)
Mr. John W. LaRocca Esq., Gen. Counsel & Assistant Sec. (Age 54, Pay $576.3k)
Mr. Jeffrey Calabrese, Director of Accounting
Ms. Ami Bavishi, Director of Investor Relations
Andrew Allen, Chief Compliance Officer
Mr. Tad Heitmann, Head of Communications
Evan Hockman, VP of Sales

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Who are Aerie Pharmaceuticals' major shareholders?

Aerie Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Frontier Capital Management Co. LLC (1.00%), DNB Asset Management AS (0.22%), Endurance Wealth Management Inc. (0.21%), Thompson Investment Management Inc. (0.07%) and OLD National Bancorp IN (0.06%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino and Vicente Anido Jr.
View institutional ownership trends for Aerie Pharmaceuticals.

Which major investors are selling Aerie Pharmaceuticals stock?

AERI stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC. Company insiders that have sold Aerie Pharmaceuticals company stock in the last year include Casey C Kopczynski, and Gerald D Cagle.
View insider buying and selling activity for Aerie Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Aerie Pharmaceuticals stock?

AERI stock was bought by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Endurance Wealth Management Inc., Thompson Investment Management Inc., and OLD National Bancorp IN. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Richard J Rubino, and Vicente Anido Jr.
View insider buying and selling activity for Aerie Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Aerie Pharmaceuticals?

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $15.07.

How big of a company is Aerie Pharmaceuticals?

Aerie Pharmaceuticals has a market capitalization of $705.50 million and generates $69.89 million in revenue each year. The company earns $-199,580,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Aerie Pharmaceuticals employs 380 workers across the globe.

What is Aerie Pharmaceuticals' official website?

The official website for Aerie Pharmaceuticals is www.aeriepharma.com.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here